Osimertinib: beside an established treatment under test
42 studies: an approved drug, surgery or radiation is what the study tests. Page 1 of 1. Open to participants first (25), then studies with results posted, then the rest; newest registration first within each.
- Osimertinib Plus Stereotactic Radiosurgery/Radiotherapy for EGFR-Mutant Non-Small Cell Lung Cancer With Symptomatic Brain MetastasesRecruitingNCT07911449Phase 2Report a problem
- Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLCRecruitingNCT07874490Phase 2Report a problem
- Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung CancerRecruitingNCT07738172Phase 3Report a problem
- OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic TherapyRecruitingNCT07655583Phase 1Report a problem
- EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLCRecruitingNCT07637448Phase 2Report a problem
- Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung CancerRecruitingNCT07505173Phase 2Report a problem
- Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung CancerRecruitingNCT07379476Phase 2Report a problem
- Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung CancerNot yet recruitingNCT07177092Phase 2Report a problem
- Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)RecruitingNCT07073365Phase 2Report a problem
- Orlistat Overcoming Third-generation EGFR-TKI ResistanceNot yet recruitingNCT06818955Phase 2Report a problem
- A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the BrainRecruitingNCT06741085Phase 2Report a problem
- CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLCNot yet recruitingNCT06557096Early Phase 1Report a problem
- Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung CancerRecruitingNCT06304441Not applicableReport a problem
- A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.Not yet recruitingNCT06142617Phase 2Report a problem
- Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer PatientsRecruitingNCT06071013Phase 1/2Report a problem
- Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung CarcinomaRecruitingNCT06014827Phase 2Report a problem
- Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)Not yet recruitingNCT05998993Not applicableReport a problem
- Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)RecruitingNCT05642572Phase 2Report a problem
- Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerRecruitingNCT05624996Phase 3Report a problem
- SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLCNot yet recruitingNCT05583409Not applicableReport a problem
- A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain MetastasesRecruitingNCT05033691Not applicableReport a problem
- Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLCNot yet recruitingNCT04988607Phase 2Report a problem
- Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBIRecruitingNCT04829019Phase 2Report a problem
- Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung CancersRecruitingNCT04410796Phase 2Report a problem
- Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerRecruitingNCT04181060Phase 3Report a problem
- A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)Active, not recruitingNCT04035486Phase 3Results postedReport a problem
- Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790MCompletedNCT03133546Phase 2Results postedReport a problem
- Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain MetastasesActive, not recruitingNCT02971501Phase 2Results postedReport a problem
- Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With OsimertinibCompletedNCT02759835Phase 2Results postedReport a problem
- Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L OsimertinibCompletedNCT04769388Phase 2Report a problem
- SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIsCompletedNCT04764214Phase 2Report a problem
- Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 MutationsActive, not recruitingNCT04695925Phase 3Report a problem
- Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC PatientsCompletedNCT04184921Phase 2Report a problem
- Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal MetastasisStatus unknownNCT04148898Phase 2Report a problem
- ctDNA Guided Treatment of Early Resistance to Targeted TreatmentCompletedNCT04148066Not applicableReport a problem
- Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT03909334Phase 2Report a problem
- Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor MutationsStatus unknownNCT03799094Phase 1/2Report a problem
- Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLCActive, not recruitingNCT03769103Phase 2Report a problem
- A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.CompletedNCT03755102Early Phase 1Report a problem
- Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLCCompletedNCT03543683Phase 2Report a problem
- A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain MetastasesCompletedNCT03497767Phase 2Report a problem
- Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR StudyActive, not recruitingNCT03410043Phase 2Report a problem